相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach
J. Snoeys et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method
T. Yoshikado et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake
Tom De Bruyn et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters
Lindsey H. M. te Brake et al.
TUBERCULOSIS (2016)
Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach
Anna Vildhede et al.
DRUG METABOLISM AND DISPOSITION (2016)
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Manthena V. Varma et al.
PHARMACEUTICAL RESEARCH (2015)
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Jennifer E. Sager et al.
DRUG METABOLISM AND DISPOSITION (2015)
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin
Thomayant Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Clinical CYP3A Inhibitor Alternatives to Ketoconazole, Clarithromycin and Itraconazole, Are Not Transported into the Liver by Hepatic Organic Anion Transporting Polypeptides and Organic Cation Transporter 1
J. William Higgins et al.
DRUG METABOLISM AND DISPOSITION (2014)
Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model
Manthena V. Varma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Hepatic Uptake of Atorvastatin: Influence of Variability in Transporter Expression on Uptake Clearance and Drug-Drug Interactions
Anna Vildhede et al.
DRUG METABOLISM AND DISPOSITION (2014)
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
Yoshihisa Shitara et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport-Mediated PK and DDIs in Humans
M. J. Zamek-Gliszczynski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Resolving the Distribution-Metabolism Interplay of Eight OATP Substrates in the Standard Clearance Assay with Suspended Human Cryopreserved Hepatocytes
Par Nordell et al.
MOLECULAR PHARMACEUTICS (2013)
Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes
Toshiyuki Kudo et al.
DRUG METABOLISM AND DISPOSITION (2013)
Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes
Nathan D. Pfeifer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats
Tomotaka Shingaki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses
J. Honkalammi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug - Drug Interactions
Maria Karlgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance
Carolina Saell et al.
DRUG METABOLISM AND DISPOSITION (2012)
Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data
Hannah M. Jones et al.
DRUG METABOLISM AND DISPOSITION (2012)
Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design
M. L. Reitman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study
K. Maeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model
Xuena Lin et al.
DRUG METABOLISM AND DISPOSITION (2011)
Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses
Johanna Honkalammi et al.
DRUG METABOLISM AND DISPOSITION (2011)
Culture Period-Dependent Changes in the Uptake of Transporter Substrates in Sandwich-Cultured Rat and Human Hepatocytes
Naoki Kotani et al.
DRUG METABOLISM AND DISPOSITION (2011)
Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans
Takao Watanabe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Ruben C. Hartkoorn et al.
PHARMACOGENETICS AND GENOMICS (2010)
Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite
Xin Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein
T. Tachibana et al.
XENOBIOTICA (2009)
Bosentan is a substrate of human OATP1B1 and OATP1B3:: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil
Alexander Treiber et al.
DRUG METABOLISM AND DISPOSITION (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist
J Dingemanse et al.
CLINICAL PHARMACOKINETICS (2004)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
分享论文
